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Abstract
Background: Polycystic ovary syndrome (PCOS) increases the risk of metabolic
syndrome (MetS). Insulin resistance (IR) plays a major role in the pathophysiology of both
PCOS and MetS.
Objective: This study was designed to compare the prevalence of MetS among different
phenotypes of PCOS and its relationship with androgenic components.
Materials and Methods: 182 participants eligible for this five-group comparative study
were selected by convenience sampling method. They were classified according to
the Rotterdam criteria: clinical and/or biochemical hyperandrogenism (H) + PCOS on
ultrasound (P) + ovulation disorders (O) (n = 41), clinical and/or biochemical H + PCOS on
P (n = 33), PCOS on P + O (n = 40), clinical and/or biochemical H + O (n = 37), and control
(without PCOS) (n = 31). MetS wasmeasured based on the National Cholesterol Education
Program Adult Treatment Panel III criteria. Androgenic components included free-
androgen-index (FAI), total-testosterone (TT) level and sex-hormone-binding-globulin
(SHBG).
Results: A significant difference was observed between the study groups in terms of
MetS prevalence (p = 0.01). In phenotype H+P+O, there was a statistically significant
positive association between TG and TT, and a significant negative association between
SBP and DBP with SHBG. In phenotype O+P, WC was inversely associated with SHBG.
In phenotype H+O, FBS and TG were positively associated with FAI but HDL was
inversely associated with FAI. Moreover, WC and DBP were positively associated with
TT in phenotype H+O. No associations were detected between MetS parameters and
androgenic components in other PCOS subjects (phenotype H+P) and in the control
group. TT was significantly higher in the PCOS group suffering from MetS (p = 0.04).
Conclusion: According to the research results, hyperandrogenic components are potent
predictors of metabolic disorders. Thus, we suggest that MetS screening is required for
the prevention of MetS and its related complications in PCOS women.
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1. Introduction
Polycystic ovary syndrome (PCOS) is the
most frequent endocrinopathic disturbance
among women of reproductive age (1). The
prevalence of PCOS among Iranian women
is 14.6% based on the Rotterdam definition
(2). As specified by the Rotterdam criteria in
2003, PCOS is diagnosed when at least two
of the following three constituents are present:
clinical and/or biochemical hyperandrogenism
(H), oligomenorrhea/amenorrhea (O), and
polycystic sonographic view in ovaries (P) (3).
Accordingly, the following four statuses are
placed in PCOS description: classic form (H + P
+ O; presence of all the three criteria); absence
of polycystic sonographic view in ovaries (H +
O); absence of hyperandrogenism (O + P); and
absence of menstrual cycle disorders (H + P).
The metabolic abnormalities related to PCOS
(specially hyperandrogenic phenotypes) are body
fat increase, dyslipidemia, insulin resistance (IR),
glucose intolerance, and hypertension (4). These
PCOS complications elevate the risk of long-
term health outcomes such as diabetes mellitus
and cardiovascular diseases (5). On the other
hand, IR is fundamental in PCOS pathophysiology
(6).
Metabolic syndrome (MetS) is a collection
of chronic metabolic derangements, which
promotes the risk of serious diseases such
as cardiovascular disturbances and diabetes
(6, 7). These metabolic disorders comprise of
dysglycemia, increased blood pressure, obesity
(particularly abdominal adiposity), dyslipidemia as
elevated levels of triglyceride, and decrease in
high-density lipoprotein cholesterol (HDL) levels
(7). Risk factors of the MetS include diabetes, a
history of gestational diabetes, obesity, IR, and
PCOS (8). Most of the metabolic disturbances of
PCOS patients overlap with the components of
MetS (6).
Hyperandrogenism (biochemical) include
laboratory evidence of hyperandrogenemia
(increase in serum androgenic components: total
testosterone (TT) and free androgen index (FAI))
(9). Hyperandrogenism (HA), which accompanies
PCOS frequently, is associated with IR (10).
Some investigators represented HA as a key
factor in IR (4). HA could be linked with some
IR-related complications such as MetS (11). Some
studies demonstrated that HA contributed in
metabolic profile changes (4). To the best of
our knowledge, there are very few studies that
have compared the prevalence of MetS in two
or three prevalent phenotypes of PCOS (8, 12).
There is a scarcity of data concerning the MetS
prevalence in four phenotypes of PCOS (13). Other
studies have addressed the evaluation of MetS
components among the phenotypes of PCOS (14,
15). Furthermore, there are lots of controversial
data obtained from various studies in this context
(14, 16-19).
Therefore, this study was designed to
compare the frequency of MetS and the
association between the components of MetS
with androgenic components (TT, FAI, and
sex hormone-binding globulin (SHBG)) among
different phenotypes of PCOS in Iranian women.
To our knowledge, this is the first study that
has addressed the relationship of MetS with
androgenic components among Iranian PCOS
women.
2. Materials and Methods
This five groups comparative study (four
phenotypes of PCOS as H + P + O, H + P,
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O + P, H + O, and one control group without
PCOS) was designed as a cross-sectional study.
Prior to conducting the study, a sample size
calculation was performed using the correlation
between serum androgenic indices and MetS
components’ levels obtained in our pilot study.
The minimum correlation coefficient obtained was
0.5 (based on the calculated correlation between
TT and triglycerides (TG)). The sample size was
calculated based on the following parameters:
study power = 80%, confidence interval = 95%.
Thus, the appropriate sample size was calculated
at at least 27 for each phenotype of PCOS
and the control group. Eventually, at least 31
women were recruited in each group to allow
the loss to follow-up. The present comparative
study was accomplished from October 2014 to
September 2015 in Tehran, Iran. Convenience
sampling method was used for the recruitment of
the study subjects. Assessment of eligibility for
participation and recruitment of the participants
were based upon the inclusion and exclusion
criteria.
The inclusion criteria were age 18-40 yr,
non-pregnant, Iranian race, and no medication
with hormones known to influence serum
androgen levels, including anti-androgenic
drugs and oral contraceptive pills during three
months before the study. Those participants
who were currently taking antihypertensive,
lipid-lowering drugs, and insulin-sensitizing
and glucose-reducing agents (due to the high
glucose level in their blood) were considered
to have hypertension, hyperlipidemia, and
hyperglycemia, respectively, and they were
excluded from the study. Due to the drug
effect on the results, we should not include
the PCOS patients who were consuming
metformin due to PCOS (not because of the
high blood glucose level). Those participants
who were not eligible for the study such as
patients with thyroid dysfunction, abnormal
prolactin levels, congenital adrenal hyperplasia
(CAH), Cushing’s syndrome (CS), androgen-
secreting tumors, and diagnosed CVD, as
well as those taking oral contraceptives and
anti-androgenic drugs were excluded from this
study.
Regarding the rarity of some phenotypes of
PCOS (especially H + P), more than 108 women
were required to be screened so that we could
complete the sample size of at least 27 in the rare
subgroups. At the end of the data collection, 197
participants were entered into the study. Of these,
15 participants were considered as withdrawn
because of failure to follow-up: (H + P + O, n = 4), (H
+ P, n = 3), (O + P, n = 2), (H + O, n = 3), and (control,
n = 3). Eventually, the number of participants in
each subgroup of PCOS and control group was
as follows: (H + P + O, n = 41), (H + P, n = 33),
(O + P, n = 40), (H + O, n = 37), and (control, n =
31).
In total, 182 participants were recruited among
the eligible women referred to the Department
of Obstetrics and Gynecology at two hospitals
and one clinic. The participants were classified
into five groups - one control group and four
different phenotypes of PCOS. The control
group included 31 non-hirsute women (without
clinical evidence of hyperandrogenism) with
regular menstrual cycles (without anovulation)
whose hormonal and sonographic assessment
results were negative in terms of PCOS as well.
These women had been selected from among
university students who are residents in Tehran,
healthy companions of the patients (not their
sister) and patients referred to the clinic for
checkup, pap test, vaginitis treatment, and other
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irrelevant reasons and without any impact on
the study results. These participants had no
history of consumption of medications related
to PCOS and MetS. The socioeconomic status
was assessed by checking the remaining income
of the participant after deducting expenses
per person in a month. The economic situation
was divided into three levels: first level (weak),
second level (average), and third level (good).
Physical activity was classified into three levels
according to the frequency of exercise for at
least 20 min per wk: none, 1-2 times/wk, and ≥ 3
times/wk.
We described PCOS using the Rotterdam
criteria by the existence of at least two of
the following three: ovulation disorders (O),
clinical and/or biochemical hyperandrogenism
(H), and PCOS on ultrasound (P). At the initial
examination, the survey of medical history, general
checkup (anthropometric measurements and
blood pressure), and classification of PCOS
patients were carried out for all participants based
on the Rotterdam criteria. At first, all participants
were questioned about the regulation of the
menstrual cycle and they were subjected to
clinical examination in order to evaluate hirsutism
based on the Ferriman-Gallwey score (FG-
score). If both of these factors were normal in
a participant, she was selected as a candidate
for the control group (if the results of ultrasound
and serum hormonal tests were also normal in
terms of PCOS, these participants were confirmed
as control group candidates). All participants
were referred to an abdominal ultrasound and
hormonal test after the initial evaluation and
clinical examination. The women were divided
into four PCOS subgroups based upon the FG-
score (hirsutism; clinical HA), serum androgen
measurement (biochemical HA), presence
or absence of PCOS sonographic view in
ultrasound evaluation, and menstrual irregularities
(amenorrhea/oligomenorrhea).
2.1. Clinical and biochemical
measurements
Anthropometric measurements, which were
performed for all participants in this study, included
body weight, height, and waist circumference
measurements. Height and weight were scaled
with the subjects in light clothes and without
shoes. Waist circumference was evaluated
using a flexible tape at the midline between
the lower rib border and the curved superior
border of the ilium (at the level of the umbilicus)
at the end of normal exhalation, whereas the
participants were in the standing position. BMI
was computed based on the World Health
Organization (WHO) guidelines (5). The calculation
formula was weight (kg) divided by height
squared (m) (kg/m2). Blood pressure (BP) was
measured using a mercury sphygmomanometer
under the following conditions: after a 10-min
rest period, taken from the right arm, loose
sleeves, non-fasting state, depleted bladder,
and avoiding eating, drinking (except water),
and smoking for at least one hr before the
test.
We described ovulation disorder as the
menstrual cycle duration in excess of 35
days or lack of menstrual cycle for more
than three months (Oligo/anovulation) (16).
We defined biochemical HA based on the
cut-off set by Hashemi and co-workers (20).
The FG-score ≥ 8 was specified as clinical
HA (21). All participants (PCOS and controls)
underwent abdominal ultrasonography.
Ovaries containing 12 or more follicles
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measuring 2-9 mm in diameter and/or enlarged
ovarian volume (> 10 mm3) on abdominal
ultrasonography were considered to have
a positive polycystic sonographic view
(3).
MetS was recognized by the presence of
three or more of the following risk factors
based on the modified National Cholesterol
Education Program Adult Treatment Panel III
guidelines (22): fasting serum glucose (FBS)
level of at least 100 mg/dl; fasting serum TG at
least 150 mg/dl, serum High-density lipoprotein
cholesterol (HDL-C) level < 50 mg/dl, systolic
blood pressure (SBP) level of at least 130
mmHg, diastolic blood pressure (DBP) level of
at least 85 mmHg, and waist circumference
(WC) of at least 95 cm in Iranian race females
(23).
Serologic hormonal and metabolic evaluations
were performed between the 2nd and the
10th days of the menstrual cycle or on any
day in amenorrheic condition. All samples
were collected between 8 and 10 am. The
specimens were drawn after overnight 12-
hr fasting for the definition of plasma HDL-
C, TG, and FBS. Blood samples were also
drawn for assessment of SHBG and TT levels.
FAI was computed by TT (nmol/L)/SHBG
(nmol/L) ×100. TG and FBS were distinguished
based on the Colorimetric-Enzymatic methods
(glucose oxidase), and HDL-C was evaluated
according to immunoinhibition methods, all of
them by commercial kits (Pars Azmoon Inc.,
Tehran, Iran) using Auto-analyzer BT2000
device. Biochemical measurement of TT
and SHBG levels was performed based
on electro-chemiluminescence method
(Roche Instr Kit, Germany) by Cobas E411
device.
2.2. Ethical consideration
This study was approved by the Ethics
Committee of Medical Sciences of Tarbiat Modares
University (IRB # 525503). All women were
informed about the project and fulfilled the written
informed consent before participating in the study.
2.3. Statistical analysis
Normal and non-normal quantitative variables
were reported as Mean ± Standard Deviation (SD)
and Median (interquartile range), respectively.
Qualitative variables were presented as number
(percentage). Primarily, the quantitative variables
were checked for normality using the Kolmogorov-
Smirnoff’s (KS) test. One-way ANOVA was applied
for the normal variables and Kruskal-Wallis
(KW) test was used for the non-normal and
ordinal variables. If there was a significant group
effect, a pairwise comparison of the groups was
performed using the Mann-Whitney’s U test (MW).
Then, Bonferroni’s correction performance (p <
0.005) was considered significant. Qualitative
variables were compared by Chi-square test
and Fisher’s exact test. In order to compare
the non-normal and normal variables between
the two PCOS groups with and without MetS,
independent Samples t test and Mann-Whitney’s
test (MW) were used, respectively. The multiple
linear regression analysis with the stepwise
method was applied to evaluate the association
between androgenic components (TT, FAI,
and SHBG) as the independent variables and
MetS components (SBP, DBP, TG, HDL, FBS,
and WC) as the dependent variables in each
group. Statistical significance was set at p
< 0.05. Data were analyzed using the SPSS
software (Statistical Package for the Social
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Sciences, SPSS Inc., Chicago, IL, USA), version
22.0.
3. Results
Table I gives some information about the Basic
features of PCOS diagnosis in each group at
the beginning of the study. According to Table
II, there is no significant difference between the
study groups in terms of age, BMI, physical
activity, educational level, and socioeconomic
status.
As shown in Table III, there is a significant
difference between the groups in terms of MetS
frequency, which is 17.1% (group H + P + O),
3% (group H + P), 2.5% (group O + P), 13.5%
(group H + O), and 0.0% (control group). All
PCOS subgroups had higher FBS compared to the
control group. There was a statistically significant
difference between phenotypes H + P + O, O +
P, and H + O of PCOS and the control group
in terms of HDL-C. Phenotypes H + P + O and
H + O showed significant difference in SBP and
DBP. Phenotype H + O and the control group
showed a significant difference in SBP. There was a
significant difference in DBP between phenotypes
H + P and H + O.
In Table IV, the androgenic components of
PCOS women with MetS (n = 14) are compared
with those without MetS who were matched in
terms of age and BMI (n = 28), regardless of
phenotype classification. Since the numbers of
PCOS women with MetS were only 14 people
and it would be underpowered in comparison
with 137 PCOS women without MetS, 28 age-
and BMI-matched participants out of 137 PCOS
women without MetS were selected and the
androgenic components (TT, FAI, and SHBG) were
compared between these two groups. TT and
FAI were significantly higher in the PCOS group
suffering from MetS. Nevertheless, there was no
significant difference in the SHBG between the
two groups. Table V gives the outcome of the
stepwise linear regression analysis, including the
TT, FAI, and SHBG as independent variables
and MetS components (FBS, HDL-C, TG, WC,
SBP, and DBP) as dependent variables in each
group separately. In phenotype H + P + O, there
is a statistically significant positive association
between TG and TT, and a significant negative
association between SBP and DBP with SHBG.
In phenotype O + P, WC is inversely associated
with SHBG. In phenotype H + O, FBS and TG are
positively associated with FAI but HDL is inversely
associated with FAI. Moreover, WC and DBP are
positively associated with TT in phenotype H + O.
However, no associations were detected between
MetS components and TT, FAI, and SHBG in
phenotype H + P and the control group (data are
not shown).
Table I. Basic features of PCOS diagnosis in each group at the beginning of the study
Parameters H + P + O group
(n = 41)
H + P group
(n = 33)
O + P group
(n = 40)




TT (nmol/L), 2.68 ± 2.05 1.70 ± 1.45 1.17 ± 0.48 1.91 ± 1.40 0.77 ± 0.57
FAI 8.9 ± 7.7 4.0 ± 4.5 3.1 ± 2.9 5.5 ± 3.6 1.4 ± 1.5
SHBG (nmol/L) 41.5 ± 27.2 51.1 ± 28.3 50.7 ± 23.0 39.8 ± 20.2 76.3 ± 45.1
FG-score 9.3 ± 2.0 9.1 ± 1.5 2.5 ± 2.2 8.7 ± 1.5 2.1 ± 1.5
Ovarian follicle counts 14.4 ± 0.9 14.6 ± 1.0 13.9 ± 1.9 5.7 ± 3.1 5.6 ± 2.4
TT: Total testosterone; FAI: Free androgen index; SHBG: Sex hormone-binding globulin; FG-score: Ferriman-Gallwey score
Data are given as Mean ± SD
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Table II. Comparison of the demographic parameters at the beginning of the study
Parameters H + P + O group
(n = 41)
H + P group
(n = 33)
O + P group
(n = 40)







28.0 (7.5) 27.0 (6.5) 26.0 (9.0) 28.0 (9.0) 29.0 (8.0) 0.09*
BMI (Kg/m2),
mean ± SD
25.4 ± 5.2 25·3 ± 5·3 25.0 ± 4.2 25.0 ± 3.9 24.9 ± 4.8 0.99**
Physical activity (exercise frequency), N (%)
None 23 (56.1) 20 (60.6) 25 (62.5) 25 (67.6) 20 (64.5)
1-2 times/week 6 (14.6) 6 (18.2) 7 (17.5) 5 (13.5) 5 (16.1)
≥ 3 times/week 12 (29.3) 7 (21.2) 8 (20.0) 7 (18.9) 6 (19.4)
0.90***
Educational level, N (%)
Basic school 4 (9.8) 3 (9.1) 4 (10.0) 2 (5.4) 2 (6.5)
High school 9 (22.0) 5 (15.2) 10 (25.0) 16 (43.2) 14 (45.2)
Bachelor 19 (46.3) 16 (48.5) 20 (50.0) 15 (40.5) 10 (32.3)
MSc & PhD 9 (22.0) 9 (27.3) 6 (15.0) 4 (10.8) 5 (16.1)
0.32***
Socioeconomic status, N (%)
First level (weak) 16 (39) 23 (69.7) 23 (57.5) 21 (56.8) 17 (54.8)
Second level
(average)
16 (39) 5 (15.2) 11 (27.5) 7 (18.9) 7 (22.6)
Third level (good) 9 (22) 5 (15.2) 6 (15) 9 (24.3) 7 (22.6)
0.20***
BMI: Body mass index
*P-value refers to the Kruskal-Wallis test; **P-value refers to the One-way ANOVA; ***P-values refer to Chi-square test
Statistical significance was set at p < 0.05.
Table III. Comparison of MetS and its components between PCOS subgroups and control group













(n = 31) P-value*
pair wise comparison;
MW, P-value
MetS (+) n (%) 7 (17.1) 1 (3) 1 (2.5) 5 (13.5) 0 (0.0) 0.01 -
FBS, median
(IQR) 91.0 (7.5) 88.0 (10.5) 87.0 (10.7) 90.0 (16.5) 79.0 (17.0) <0.001
A & Control, p < 0.001
B & Control, p = 0.001
C & Control, p = 0.005
D & Control, p = 0.004
HDL-C, median
(IQR) 45.0 (16.5) 52.0 (15.0) 51.5 (13.2) 49.0 (13.0) 56.0 (10.0) <0.001
A & Control, p < 0.001
C & Control, p = 0.002
D & Control, p < 0.001
TG, median
(IQR) 126.0 (93.5) 94.0 (86.5) 90.5 (77.0) 99.0 (91.5) 85.0 (70.0) 0.40 -
WC, median
(IQR) 85.0 (14.5) 81.0 (11.0) 82.0 (11.5) 84.0 (12.7) 81.0 (15.0) 0.65 -
SBP, median
(IQR) 110.0 (16.0) 110.0 (13.0) 114.5 (10.0) 118.0 (16.0) 110.0 (13.0) <0.001
A & D, p = 0.003
D & Control, p = 0.004
DBP, median
(IQR) 68.0 (27.5) 70.0 (15.0) 74.5 (20.0) 79.0 (10.0) 70.0 (12.0) 0.01
A & D, p = 0.003
B & D, p = 0.003
MetS: Metabolic syndrome; FBS: Fasting blood sugar; HDL-C: High-density lipoprotein cholesterol; TG: Triglyceride; WC: Waist
circumference; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MW: Mann-Whitney’s U test
*P-values refer to the Kruskal-Wallis test followed by appropriate post hoc test (Mann-Whitney U test) (p< 0.005 was considered
significant for multiple comparisons based on Bonferroni correction); p-value for the variable MetS refers to the Fisher’s exact
test (p < 0.05 was considered significant)
Significant results are shown in the table exclusively
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Table IV. Comparison of androgenic components between PCOS women with and without MetS
PCOS P-valueAndrogenic components
MetS (+) n = 14 MetS (-) n = 28
TT (nmol/L) 3.42 ± 3.02 1.09 ± 0.61 < 0.001*
FAI 9.91 ± 9.57 3.85 ± 3.53 0.022**
SHBG (nmol/L) 37.67 ± 13.47 39.88 ± 19.60 0.708*
PCOS: Polycystic ovary syndrome; MetS: Metabolic syndrome; TT: Total testosterone; FAI: Free androgen index; SHBG: Sex
hormone binding globulin
Data presented as Mean ± SD. *P-value refers to the independent samples t test; **P-value refers to the Mann-Whitney’s U
procedure.





B SE P-value Adjusted R2
A TG 45.215 16.471 0.009 0.14
WC 8.719 4.122 0.040 0.08TT D
DBP 14.769 6.566 0.031 0.10
FBS 0.901 0.382 0.026 0.11
HDL-C -1.338 0.395 0.002 0.22FAI D
TG 7.312 2.015 0.001 0.25
SBP -0.138 0.058 0.020 0.10A
DBP -0.171 0.071 0.022 0.10SHBG
C WC -0.160 0.058 0.009 0.14
The models included TT, FAI, and SHBG as predictors, dependent variables included MetS components. Except for the
independent variables shown, there were no significant relationships between the other variables
FBS: Fasting blood sugar; HDL-C: High-density lipoprotein cholesterol; TG: Triglyceride; WC: Waist circumference; SBP: Systolic
blood pressure; DBP: Diastolic blood pressure; TT: Total testosterone; FAI: Free androgen index; SHBG: Sex hormone-binding
globulin; B: Unstandardized coefficient; SE: Standard error
H.P.O. A: H + P + O; B: H + P; C: O + P; D: H + O
Statistical significance was set at p < 0.05
4. Discussion
This study compared the MetS ingredients
between different phenotypes of PCOS and
normal participants in a sample of Iranian
women. The results showed that the frequency
of MetS is significantly higher in all phenotypes
of PCOS compared with the control group. It is
necessary to mention that non-hyperandrogenic
phenotype of PCOS (phenotype O + P) has
the lowest frequency of MetS among all PCOS
women. Hyperandrogenism, as the most eminent
diagnostic indicator of PCOS, and its indices
substantially depend on age, race, ethnicity
and body weight. Several studies have so
far been conducted to assess the prevalence
of MetS among PCOS women with various
phenotypes in different races. In concordance
with our results, Kavardzhikova and colleagues
illustrated significant differences in anthropometric,
hormonal and metabolic components between
the different phenotypes of PCOS (24). Also,
Goverde and co-workers reported that the
prevalence of metabolic derangements and IR
varies between different phenotypes of PCOS.
They described that hyperandrogenic phenotypes
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of PCOS have a higher prevalence of MetS
and IR (25). In addition, the results of Jamil and
colleagues study are relatively in accordance
with our findings although they reported the
highest prevalence of MetS in phenotype H +
O, which can be justified by high BMI (26). In
this study, hyperandrogenic subgroups of PCOS
(subgroup H + P + O had the most frequency
of MetS) showed a higher frequency of MetS.
Furthermore, we omitted confounder BMI and age
by matching between the participants. Conversely,
Hosseinpanah and co-workers observed no
difference in the MetS components of different
PCOS phenotypes (27). The feasible explanation
behind the aforementioned contradiction can
be slight differences in the inclusion criteria,
genetic factors, lifestyle characteristics, and
dietary habits. Moreover, the studied groups in
their research had a considerable difference in
terms of participants’ number. In accordance with
our findings, Diamanti-Kandarakis and colleagues
have also considered hyperandrogenemia as a
contributing factor in MetS development among
PCOS women (28). It is obvious that subgroup
H + P + O, as a classic form of PCOS, has worse
status than the others. Therefore, it seems that the
highest prevalence of MetS in this phenotype of
PCOS is justifiable. In agreement with the present
study results, Pehlivanov and co-workers indicated
that phenotype H + P + O PCOS patients (full
Rotterdam) were more obese, with considerably
higher expressed hyperandrogenemia and IR
compared with other phenotypes of PCOS (29).
We also found that among all the components
of MetS, FBS, HDL, SBP, and DBP showed
significant differences between the different
groups. However, FBS alone displayed significantly
higher amounts in all phenotypes of PCOS than the
control group. Also, HDL values in all phenotypes
of PCOS except phenotype H + P were lower
than in the control group. Similar to our study,
Zahiri and colleagues reported a significant
difference in MetS components between different
phenotypes of PCOS and the control group (13).
Thus far, several studies have been conducted
in order to investigate MetS prevalence and
metabolic profile changes in four phenotypes of
PCOS. Zhang and co-workers reported 28.5%,
25.5%, 8.3%, and 7.2% of MetS frequency in H
+ P + O, H + O, H + P, and O + P phenotypes
of PCOS, respectively, as compared to 3.5%
in controls (19). Additionally, they found that
some metabolic components (total cholesterol,
low-density lipoprotein, TG, and HDL) were
significantly different between the phenotypes
of PCOS and control group. The results of the
present study confirmed the highest frequency
of MetS in the H + P + O group. However, the
prevalence of MetS in all phenotypes of PCOS
and controls was lower in the present study. In
this study, the majority of participants (in the
control group and PCOS subgroups) were very
young and had lower BMI. This is a very important
group of women to target for further intervention
and prevention strategies in the development
of MetS. Furthermore, all individuals who were
consuming antihypertensive, lipid, and glucose-
lowering drugs were not included in the study.
Also, different diagnostic criteria (International
Diabetic Federation) of MetS were used in their
study. Low prevalence of MetS in four phenotypes
of PCOS and zero prevalence in controls in
this study can be caused by these points. Also,
Kar and colleagues evaluated the metabolic
profile of the four Rotterdam PCOS phenotypes.
Contrary to the present study results, they found
no significant difference in metabolic components
except for WC between groups (14). Absence
of the age- and BMI-matched control group to
PCOS phenotypes in their study can justify this
contradiction. The significant differences observed
in the metabolic components in the present study
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were often between the PCOS subgroups and the
control group. Furthermore, there was a notable
difference in the sample size in the four groups
in Kar’s study (14). phenotype P + H included
only 0.9% (n = 4), and by contrast, phenotype
H + P + O comprised 65.6% (n = 269) out of all
participants that could reduce the study power.
Tripathy and co-workers reported that WC was
significantly greater in phenotypes H + P + O and
H + O (15). They also represented the increased
serum levels of HDL-C in H + P + O and H + O
as compared to phenotype O + P and controls.
Additionally, significant increased level of TG in
phenotypes H + P + O and H + O compared to
other groups was displayed. MetS prevalence
was 33.6%, 36.7%, 24.4%, 11.6%, and 10.1% in
phenotype H + P + O, H + O, H + P, O + P, and
controls, respectively. The method used in the
mentioned study had contained some subtle
differences: Not matching between groups in
terms of age and BMI and striking difference in
sample size between four phenotypes with each
other and controls. These observed differences
can be attributed to match the participants in terms
of BMI. Moreover, observed differences in results
of the various studies may be justified by the
impression of genetic diversity between various
ethnic populations and different environmental
factors and also by delicate differences in the
selected methods and inclusion criteria used by
each of them.
It is worth noting that numerous studies have
examined the impact of hyperandrogenism on
the MetS components separately though the
majority of them were performed in a group
of PCOS without phenotype consideration (30,
31). As a novel work, we analyzed the effect of
androgenic predictive factors onMetS components
in all phenotypes of PCOS separately. Our
results demonstrated the undesirable impact
of androgenic ingredients on MetS components.
Furthermore, we found a significantly higher level
of TT and FAI in PCOSwomenwith MetS compared
with those without MetS. Kar and co-workers also
compared the androgenic components values
(TT, free testosterone, and SHBG) between the
two PCOS groups with and without MetS. They
found no significant difference in mentioned
components between the groups (14). This result
could likely be different if BMI and age matching
were applied between the two groups. Since,
FAI is an androgenic component derived from
a formula (TT (nmol/L)/SHBG (nmol/L) × 100),
this component is affected by TT and SHBG. A
significant increase in FAI in PCOS patients with
MetS compared with those without MetS (as a
result of the present study) can be affected by
a significant increase in TT in these individuals.
Indeed, it can be stated that TT is more relevant to
MetS, and a significant increase in this component
has led to an increase in FAI in these patients.
The higher FAI-relevant P-value can be influenced
by SHBG which does not show any significant
difference between the two groups. Moreover, it
seems that TT could be a more potent predictor
of MetS components than FAI and SHBG. Based
on the results of linear regression analysis, the
effectiveness of TT on MetS components was
more potent compared with FAI and SHBG.
Some of the previous studies evidenced that
hyperandrogenemia has adverse effects on
abnormal lipid profile (32, 33).
The findings of Dreno B and co-workers study
have indicated that there is a correlation between
androgenic components and the number of MetS
components (34). The results of Fruzzetti and
co-workers study, in favour of this relationship,
showed a significant positive correlation between
free testosterone and FAI with the number of
MetS components, whereas SHBGhad a significant
negative correlation with MetS components (35).
This study has three valuable strengths: 1) Strict
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inclusion criteria of the study reduced greatly the
confounding factors; 2) Other factors, which can
influence our results, were removed by matching;
3) The study investigated the association of
hyperandrogenic elements with MetS components
separately in all phenotypes of PCOS. However,
this is a cross-sectional study, and since the cross-
sectional designs limit the data interpretation to
the correlation association between variables, it is
suggested to carry out more cohort or case-control
studies in future to achieve a causal relationship.
Moreover, the participants in the present study
were very young cohort average below 27 years
old and their mean BMI was around 25. Maybe
if their age and MBI were higher, it would be
more possible for the frequency of MetS to be
more. It is recommended to conduct a long-term
study (cohort) in this field to get more accurate
results.
5. Conclusion
The findings of the present study confirm
the presence of metabolic changes in PCOS
patients. It was also revealed that there are
significant differences in the metabolic profiles
among different PCOS phenotypes. According
to our results, hyperandrogenic components
per se (TT, FAI, and SHBG) could be predictors
of metabolic disorders and thus increased risk
of MetS. It is notable that our results were not
suggesting a routine investigation of androgenic
parameters as a part of the evaluation of PCOS
patients in order to prevent from MetS. This
topic needs longer investigations (cohort) with
more sample sizes. We propose that MetS
screening and a metabolic inspection could
be lucrative to prevent MetS and its related
complications in PCOS women, at least in Iranian
women.
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